source
- German biotech Immatics eyes pivotal Phase 3 readout after promising uveal melanoma cell therapy resultsImmatics, a German biotech founded 26 years ago, is focusing on cancer immunotherapy. Its lead candidate is an experimental cell therapy targeting uveal melanoma. Early Phase 1 data in 16 patients…
- FDA cites Baxter’s inadequate oversight after repeated GMP violations at multiple plantsThe U.S. Food and Drug Administration has issued a warning letter to Baxter International, saying the company's leadership has failed to provide adequate oversight of its drug manufacturing operati…